Zobrazeno 1 - 6
of 6
pro vyhledávání: '"YoonA Jung"'
Publikováno v:
Biomedicines, Vol 11, Iss 3, p 785 (2023)
Bioceramics are calcium-phosphate-based materials used in medical and dental implants for replacing or repairing damaged bone tissues; however, the effect of bioceramic sintering on the intracellular signaling pathways remains unknown. In order to ad
Externí odkaz:
https://doaj.org/article/574da521166d4e3095599758bb0f0b03
Autor:
Yoona Jung, Won-Hyeon Kim, Sung-Ho Lee, Kyung Won Ju, Eun-Hee Jang, Sung-O Kim, Bongju Kim, Jong-Ho Lee
Publikováno v:
Materials, Vol 13, Iss 19, p 4391 (2020)
Bone graft material is essential for satisfactory and sufficient bone growth which leads to a successful implant procedure. It is classified into autogenous bone, allobone, xenobone and alloplastic materials. Among them, it has been reported that het
Externí odkaz:
https://doaj.org/article/fa6adfb6f92341f6bae8e3cf41868e48
Autor:
Yoona Jung1, Wonjoon Kim2, Na Kyoung Shin1, Young Min Bae1,3, Jinhong Wie1,3 jinhongw@kku.ac.kr
Publikováno v:
Korean Journal of Physiology & Pharmacology. Jul2023, Vol. 27 Issue 4, p311-323. 13p.
Publikováno v:
International journal of medical sciences. 19(12)
Octacalcium phosphate (OCP), a type of bioactive ceramics, may be associated with dentine, tooth apatite, and especially bone generation, and promotes wound healing after fracture. Recently, commercial bone grafting products containing a large amount
Autor:
Jong-Ho Lee, Kyung Won Ju, Yoona Jung, Eun-Hee Jang, Sung-O Kim, Won-Hyeon Kim, Bongju Kim, Sung Ho Lee
Publikováno v:
Materials
Materials; Volume 13; Issue 19; Pages: 4391
Materials, Vol 13, Iss 4391, p 4391 (2020)
Materials; Volume 13; Issue 19; Pages: 4391
Materials, Vol 13, Iss 4391, p 4391 (2020)
Bone graft material is essential for satisfactory and sufficient bone growth which leads to a successful implant procedure. It is classified into autogenous bone, allobone, xenobone and alloplastic materials. Among them, it has been reported that het
Publikováno v:
Cancer Research. 78:899-899
Because about 10% of gastric cancers show amplification of FGFR2, inhibition of FGFR2 activation has been regarded as one of therapeutic targets. AZD4547, a selective inhibitor of the FGFR1-3 tyrosine kinases, was developed to inhibit FGFR signaling;